In our previous study, patients with inflammatory bowel diseases eligible for biologic therapy had significantly reduced MPO levels in the saliva of patients with ulcerative colitis (UC) compared to patients with Crohn’s disease (CD) and healthy controls. This evidence concerns the gene MPO and ulcerative colitis.